How do we reach the goal of personalized medicine for neuroprotection in neonatal hypoxic-ischemic encephalopathy?

Zhou, Kelly Q.; Dhillon, Simerdeep K.; Bennet, Laura; Davidson, Joanne O.; Gunn, Alistair J.

doi:10.1016/j.semperi.2024.151930

Seminars in Perinatology

2024

DOI: 10.1016/j.semperi.2024.151930

|View full text |Cite

How do we reach the goal of personalized medicine for neuroprotection in neonatal hypoxic-ischemic encephalopathy?

Kelly Q. Zhou,

Simerdeep K. Dhillon,

Laura Bennet

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Cerebral blood flow in neonatal encephalopathy: biomarker or potential target?

Charlton,

Kanwal

2024

Pediatr Res

View full text Add to dashboard Cite

Cerebral blood flow in neonatal encephalopathy: biomarker or potential target?

Charlton,

Kanwal

2024

Pediatr Res

View full text Add to dashboard Cite

Neuroprotection for neonatal hypoxic–ischemic encephalopathy: A review of novel therapies evaluated in clinical studies

Chan,

Hawkins,

Rodrigues

et al. 2024

Develop Med Child Neuro

View full text Add to dashboard Cite

Therapeutic hypothermia is an effective therapy for moderate‐to‐severe hypoxic–ischemic encephalopathy (HIE) in infants born at term or near‐term in high‐resource settings. Yet there remains a substantial proportion of infants who do not benefit or who will have significant disability despite therapeutic hypothermia. Novel investigational therapies that may confer additional neuroprotection by targeting known pathogenic mechanisms of hypoxic–ischemic brain injury are under development. This review focuses on putative neuroprotective agents that have shown promise in animal models of HIE, and that have been translated to clinical studies in neonates with HIE. We include agents that have been studied both with and without concurrent therapeutic hypothermia. Our review therefore addresses not just neonatal HIE in high‐resource countries where therapeutic hypothermia is the standard of care, but also neonatal HIE in low‐ and middle‐income countries where therapeutic hypothermia has been shown to be ineffective, and where the greatest burden of HIE‐related morbidity and mortality exists.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

How do we reach the goal of personalized medicine for neuroprotection in neonatal hypoxic-ischemic encephalopathy?

Cited by 2 publications

References 74 publications

Cerebral blood flow in neonatal encephalopathy: biomarker or potential target?

Cerebral blood flow in neonatal encephalopathy: biomarker or potential target?

Neuroprotection for neonatal hypoxic–ischemic encephalopathy: A review of novel therapies evaluated in clinical studies

Contact Info

Product

Resources

About